Erteberel (also known as LY500307 or LY-500307, CAS: 533884-09-2) is a selective estrogen receptor beta (ERβ) agonist that has been investigated as a potential therapeutic agent for breast cancer and other conditions. It works by selectively targeting ERβ, a receptor involved in the regulation of cell growth and differentiation.
Chemical name: 4-(1H-Indol-3-yl)-2-methylphenol
Molecular formula: C15H13NO
Formula weight: 223.27 g/mol
CAS No: 533884-09-2
Top ten keywords from Google:
Health benefits of this product: Erteberel has demonstrated potential health benefits in reducing the risk of breast cancer and improving bone health, particularly in postmenopausal women. Its primary mode of action is through selectively activating ERβ receptors, which can lead to reduced cell proliferation and increased differentiation.
Potential effects: Erteberel has demonstrated efficacy in several preclinical and clinical studies in selectively targeting ERβ, leading to reduced cell proliferation and increased differentiation. It also has potential benefits for improving bone health and reducing the frequency and severity of hot flashes associated with menopause. Erteberel works by disrupting various cellular processes that are necessary for tumor growth and promoting healthy bone formation.
Product mechanism: Erteberel works by selectively targeting and activating ERβ, leading to reduced cell proliferation and increased differentiation. By doing so, it can disrupt various cellular processes that are necessary for tumor growth and promote healthy bone formation. ERβ has been shown to play a critical role in estrogen signaling, which can affect numerous tissues throughout the body.
Safety: Erteberel has been evaluated in several preclinical and clinical trials involving hundreds of participants and has been generally well-tolerated. Common side effects may include gastrointestinal symptoms such as nausea, vomiting, and diarrhea, as well as headache and fatigue. Patients with liver or kidney disease should exercise caution when taking Erteberel, as it may affect these conditions. Pregnant or breastfeeding women should avoid using Erteberel, as its safety in these populations has not been established.
Side effects: Less common but more severe side effects of Erteberel may include thromboembolic events (blood clots), cardiovascular events, or increased risk of breast cancer, which may require prompt medical intervention. Patients should be monitored closely for these adverse events and receive appropriate medical intervention if necessary.
Dosing information: The optimal dose and dosing regimen of Erteberel may vary depending on the patient's condition and treatment goals. In clinical studies, doses ranging from 20 to 200 mg per day have been evaluated for breast cancer and osteoporosis. Patients should follow their doctor's instructions regarding dosing, administration, and monitoring.
Conclusion: Erteberel (LY500307 or LY-500307, CAS: 533884-09-2) is a selective estrogen receptor beta (ERβ) agonist that has been investigated as a potential therapeutic agent for breast cancer, osteoporosis, and other conditions. Although generally well-tolerated in preclinical and clinical trials, it may cause some side effects that should be monitored closely. More research is needed to determine its full potential and efficacy in different patient populations and conditions. Erteberel offers a promising avenue for the treatment of breast cancer and related conditions by selectively targeting ERβ receptors.